Durvalumab Side Effects: Common, Severe, Long Term
Did You Know – IMFINZI® (durvalumab) for unresectable Stage 3 NSCLC
Cost-Effectiveness Analysis of Atezolizumab Versus Durvalumab as First-Line Treatment of Extensive-Stage Small-Cell Lung Cancer in the USA | Clinical Drug Investigation
IJMS | Free Full-Text | Infections and Immunotherapy in Lung Cancer: A Bad Relationship?
Durvalumab Immunotherapy: Nursing Management of Immune-Related Adverse Events During the Journey of Patients With Stage III Non-Small Cell Lung Cancer | ONS
Does immunotherapy have side effects? | MD Anderson Cancer Center
Tremelimumab plus Durvalumab in Unresectable Hepatocellular Carcinoma | NEJM Evidence
Frontiers | Adverse Effects of Anti-PD-1/PD-L1 Therapy in Non-small Cell Lung Cancer
Tremelimumab-actl (Imjudo) Drug Information
Durvalumab Side Effects: Common, Severe, Long Term
Long-Term Side Effects of Immune Checkpoint Inhibitors - NCI
Patient-reported outcomes with durvalumab by PD-L1 expression and prior chemoradiotherapy-related variables in unresectable stage III non-small-cell lung cancer | Future Oncology
Endocrinopathies from checkpoint inhibitors: Incidence, outcomes, and management | Cleveland Clinic Journal of Medicine
Immunotherapy: Pushing the Frontier of Cancer Medicine | AACR Cancer Progress Report
Immune-checkpoint inhibitors: long-term implications of toxicity | Nature Reviews Clinical Oncology
Education & Resources for Oncology Nurses – IMFINZI® (durvalumab)
Diagnostics | Free Full-Text | Immune-Related Uncommon Adverse Events in Patients with Cancer Treated with Immunotherapy
Immunotherapy and its side effects | Cancer Research UK
Durvalumab (Imfinzi) Drug Information
Clinical Activity, Tolerability, and Long-Term Follow-Up of Durvalumab in Patients With Advanced NSCLC - ScienceDirect
Durvalumab plus tremelimumab for the treatment of advanced neuroendocrine neoplasms of gastroenteropancreatic and lung origin | Nature Communications
Tremelimumab plus Durvalumab in Unresectable Hepatocellular Carcinoma | NEJM Evidence
Reimagining Treatment for Unresectable Stage III Non-Small Cell Lung Cancer - Cancer Therapy Advisor
Immune Checkpoint Inhibitor Side Effects & Toxicity More Common Than Reported - CancerConnect
Durvalumab - Wikipedia
Durvalumab (Imfinzi) Drug Information
